PLAGIARISM SCAN REPORT

Date 2023-03-06

0%
100%

Words 452
Plagiarised Unique

Characters 3064

Content Checked For Plagiarism

Frequent Aspirin Use Lowers Ovarian Cancer Risk Regardless of Genetic Risk: New Study Revealed

Any cancerous growth that begins in the ovaries is referred as ovarian cancer. According to the American Cancer Society,
ovarian cancer is the fifth most common malignancy among women to cause death in the country. Despite advances in
treatment, the prognosis for ovarian cancer remains poor. Therefore, identifying modifiable risk factors that can reduce the
incidence of ovarian cancer is of great importance.

Patients suffering from ovarian cancer possesses poor survival rates, which makes the preventive measures crucial.
Evidence suggests that frequent aspirin use can reduce the risk for ovarian cancer by about 13%, but it's unclear whether
genetic factors change those odds.

Although promising for chemoprevention, aspirin use can also have drawbacks, such as hemorrhagic stroke and gastric
ulcers, therefore it's critical to identify and target people who are more likely to develop ovarian cancer and who might
benefit from frequent aspirin use.

A recent study published in the journal JAMA Oncology has found that frequent aspirin use can lower the risk of ovarian
cancer, regardless of genetic risk factors.

The study found that daily or almost daily aspirin use was associated with a 13% reduction in ovarian cancer risk, which was
not modified by an individual's polygenic score (PGS).

A polygenic score (PGS), which measures the total number of genetic variants an individual has that increases their chance
of getting a certain disease, was used in the current investigation to characterise genetic susceptibility to ovarian cancer. A
PGS combined with additional risk factors for diseases can provide a more accurate prediction of occurring a particular
disease than any one taken separately.

The research involved the pooled analysis of eight case-controlled studies from the Ovarian Cancer Association
Consortium carried out over a 14-year period in the UK, the US, and Australia. The researchers examined genetic and
frequent use aspirin data among 4476 patients with nonmucinous ovarian cancer (average age 57) and 6659 control
participants (average age 58). Frequent use of Aspirin was reported in 1030 controls (15%) and 575 patients (13%).

According to the scientists, using aspirin frequently was linked to a 13% decreased incidence of nonmucinous ovarian
cancer. Notably, this connection was unaffected by polygenic score.

reductions, and there is no proof that polygenic
High-grade serous and endometrioid tumours showed the highest risk
score changed this association.

In conclusion, the new study provides compelling evidence that frequent aspirin use can lower the risk of ovarian cancer,
regardless of genetic risk factors. The findings suggest that aspirin may be a promising and accessible strategy for ovarian
cancer prevention. Further research is needed to fully understand the potential benefits and risks of aspirin use for ovarian
cancer prevention.

Matched Source

No plagiarism found

Page 1 of 2
Page 2 of 2